A Phase I Study of DMOT4039A, an Antibody-Drug Conjugate Targeting Mesothelin, in Patients with Unresectable Pancreatic or Platinum Resistant Ovarian Cancer

**BACKGROUND**

- Found in normal mesothelial cells (peritoneum, pericardium, pleura)
- Over-expressed in pancreatic and ovarian cancer

**STUDY DESIGN**

**RESULTS**

**Patient Characteristics**

- Data cut-off for current analysis: 25 February 2014
- 54 patients enrolled in the every 3-week dosing schedule included in the 19 patients: 19 patients with ovarian cancer and 35 patients with pancreatic cancer

**Biomarkers**

- DMOT4039A at a dose of 2.4 mg/kg IV q3wks with CT following cycle 2 showing partial response confirmed after cycle 4 scan. Patient progressed after cycle 8.

**CONCLUSIONS**

- DMOT4039A has an acceptable safety and tolerability profile. Most AEs were Grade 1/2, and the majority of AEs were self-limited that did not require intervention. The most common AEs related to treatment included fatigue, nausea, diarrhea, anorexia, and pyrexia.

**ACKNOWLEDGMENTS**

- Thank you to the many patients for their participation in this trial
- Genentech, Inc. provided support for the preparation of this poster